News

Alvine is at present conducting Phase 2 trials with ALV003, an orally administered mixture of two recombinant gluten-specific proteases, a cysteine protease and a prolyl endopeptidase, in conjunction

The new plant will serve processors of infant formula, beverage, baby food and other food products in Asia Pacific. LycoRed sales and marketing VP Ilan Ron said LycoRed

The OmniRat technology generates fully human antibodies with specificity, affinity and manufacturability, according to WuXi. The technology eradicates time-consuming humanization of traditional mouse-derived antibodies and the need to

Mylan CEO Heather Bresch said Mylan’s mission is to provide the world’s 7 billion people access to medicines and help ensure access to ARVs. ”Only through access to

Bosulif is a kinase inhibitor that stops the cancer cell growth by inhibiting the Abl and Src signaling pathways. The drug is the only therapy approved with pivotal

The GOBIOM is a collection of 15,500 clinically evaluated, exploratory and preclinical biomarkers associated with diverse therapeutic areas reported in global clinical trials, clinical and preclinical studies. GVK

Previously, Clarke served as the company’s chief scientific officer and vice president of research and development, where he was involved in developing iCALM and iSPERSE technologies, designed for

A cyclosporine derivative, SCY-641, is the first partnered compound from the Scynexis cyclophilin inhibitor platform, which includes a clinical candidate for the treatment of Hepatitis C, SCY-635. Scynexis

The new contract with the US Department of Defense’s (DoD) Joint Project Manager Transformational Medical Technologies (JPM-TMT) program, will allow Sarepta to evaluate the tolerability, pharmacokinetics, and efficacy